Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hazard ratios for secondary outcomes, comparing SGLT2 inhibitors with DPP4 inhibitors, were 0.99 (0.85 to 1.17) for myocardial infarction, 0.94 (0.77 to 1.15) for stroke, 0.84 (0.65 to 1.08) for cardiovascular death, and 0.80 (0.69 to 0.92) for any cause death.
|
31467044 |
2019 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study.
|
31792991 |
2019 |
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess the cardiovascular efficacy of SGLT2 inhibitors or GLP-1RAs with regard to a three-point composite measure of major adverse cardiovascular events (non-fatal stroke, non-fatal myocardial infarction and cardiovascular mortality).
|
30653708 |
2019 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibition reduced the risk of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (RR, 0.81; 95% CI, 0.70-0.94) and heart failure (RR, 0.61; 95% CI, 0.48-0.78), without a clear effect on all-cause mortality (HR, 0.86; 95% CI, 0.73-1.01).
|
30697905 |
2019 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
This meta-analysis indicated that SGLT2 inhibitor therapy did not increase stroke incidence, and no significant differences in stroke risk were observed among 3 SGLT2 inhibitors (class effect).
|
29573118 |
2018 |
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non-fatal myocardial infarction, non-fatal stroke or cardiovascular mortality), hospitalization for heart failure (HHF), atrial fibrillation and severe hypoglycaemia in patients with type 2 diabetes (T2D) in a real-world setting.
|
28771923 |
2018 |
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
|
29569378 |
2018 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Two network meta-analyses concluded that sodium-glucose cotransporter 2 (SGLT2) inhibitors, mostly due to empagliflozin, decrease all-cause and cardiovascular mortality but increase the risk of nonfatal stroke, genital infection, and volume depletion.
|
29285488 |
2017 |
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As for DPP-4 inhibitors, there was a non-significant trend towards benefit for stroke, whereas a possible increased risk of stroke with SGLT2 inhibitors-and in particular, empagliflozin in the EMPA-REG OUTCOME trial-has been suggested and requires clarification.
|
28522196 |
2017 |
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
|
27895093 |
2017 |